Pharmacological significance of palbociclib and its derivatives in cancer treatment and prevention: an update

IF 2.6 4区医学 Q3 CHEMISTRY, MEDICINAL

Medicinal Chemistry Research Pub Date : 2025-04-25 DOI:10.1007/s00044-025-03411-7

Shagufta, Irshad Ahmad, Laila Zeyad Bazbouz, Noora Ali Nasar, Fatme Ghassan Ibrahim, Dana Mahmoud Alkheder

{"title":"Pharmacological significance of palbociclib and its derivatives in cancer treatment and prevention: an update","authors":"Shagufta, Irshad Ahmad, Laila Zeyad Bazbouz, Noora Ali Nasar, Fatme Ghassan Ibrahim, Dana Mahmoud Alkheder","doi":"10.1007/s00044-025-03411-7","DOIUrl":null,"url":null,"abstract":"<div><p>Palbociclib is a selective cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor that emerged as a significant therapeutic agent in the treatment of hormone receptor-positive, HER2-negative breast cancer. This review comprehensively highlights the pharmacological significance of palbociclib and its recently developed derivatives, focusing on mechanisms of action, chemical synthesis strategies, pharmacological profile and potential benefits in cancer treatment. We explored the rationale behind structural modifications and chemical derivatization of palbociclib that have been developed to enhance its therapeutic efficacy and mitigate side effects. This review offers an update on the latest advancement in palbociclib derivatives and explores their potential to improve therapeutic efficacy with minimal side effects. The detailed analysis of recent developments and ongoing research will support the designing of more efficient CDK4/6 inhibitors and provide direction in development of future cancer treatment. We anticipate that the information provided in this review will be beneficial to readers and scientist working towards development of effective cancer treatment specifically towards next-generation CDK4/6 inhibitors with improved therapeutic and safety profiles.</p><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":699,"journal":{"name":"Medicinal Chemistry Research","volume":"34 6","pages":"1237 - 1252"},"PeriodicalIF":2.6000,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicinal Chemistry Research","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s00044-025-03411-7","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Palbociclib is a selective cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor that emerged as a significant therapeutic agent in the treatment of hormone receptor-positive, HER2-negative breast cancer. This review comprehensively highlights the pharmacological significance of palbociclib and its recently developed derivatives, focusing on mechanisms of action, chemical synthesis strategies, pharmacological profile and potential benefits in cancer treatment. We explored the rationale behind structural modifications and chemical derivatization of palbociclib that have been developed to enhance its therapeutic efficacy and mitigate side effects. This review offers an update on the latest advancement in palbociclib derivatives and explores their potential to improve therapeutic efficacy with minimal side effects. The detailed analysis of recent developments and ongoing research will support the designing of more efficient CDK4/6 inhibitors and provide direction in development of future cancer treatment. We anticipate that the information provided in this review will be beneficial to readers and scientist working towards development of effective cancer treatment specifically towards next-generation CDK4/6 inhibitors with improved therapeutic and safety profiles.

查看原文本刊更多论文

帕博西尼及其衍生物在癌症治疗和预防中的药理意义：最新进展

Palbociclib是一种选择性细胞周期蛋白依赖性激酶4和6 （CDK4/6）抑制剂，在治疗激素受体阳性、her2阴性乳腺癌中成为一种重要的治疗药物。本文综述了帕博西尼及其衍生物的药理意义，重点介绍了其作用机制、化学合成策略、药理特征及其在癌症治疗中的潜在益处。我们探索了帕博西尼的结构修饰和化学衍生化背后的基本原理，这些修饰和化学衍生化已经被开发出来，以增强其治疗效果和减轻副作用。本文综述了帕博西尼衍生物的最新进展，并探讨了其以最小副作用提高治疗效果的潜力。对最新进展和正在进行的研究的详细分析将支持设计更有效的CDK4/6抑制剂，并为未来癌症治疗的发展提供方向。我们期望本综述提供的信息将对致力于开发有效癌症治疗的读者和科学家有益，特别是针对具有更好治疗性和安全性的下一代CDK4/6抑制剂。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medicinal Chemistry Research 医学-医药化学

CiteScore

4.70

自引率

3.80%

发文量

162

审稿时长

5.0 months

期刊介绍： Medicinal Chemistry Research (MCRE) publishes papers on a wide range of topics, favoring research with significant, new, and up-to-date information. Although the journal has a demanding peer review process, MCRE still boasts rapid publication, due in part, to the length of the submissions. The journal publishes significant research on various topics, many of which emphasize the structure-activity relationships of molecular biology.